779 related articles for article (PubMed ID: 22659329)
1. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
Shen DW; Pouliot LM; Hall MD; Gottesman MM
Pharmacol Rev; 2012 Jul; 64(3):706-21. PubMed ID: 22659329
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
3. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNAs as biotargets in cisplatin-based drug resistance.
Abu N; Hon KW; Jeyaraman S; Jamal R
Future Oncol; 2018 Dec; 14(29):3085-3095. PubMed ID: 30468082
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.
Shen DW; Ma J; Okabe M; Zhang G; Xia D; Gottesman MM
J Cell Physiol; 2010 Nov; 225(3):822-8. PubMed ID: 20589834
[TBL] [Abstract][Full Text] [Related]
8. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
11. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
13. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
14. Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells.
Shi S; Huang X; Ma X; Zhu X; Zhang Q
PLoS One; 2020; 15(5):e0225290. PubMed ID: 32369495
[TBL] [Abstract][Full Text] [Related]
15. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.
Fu R; Zhao B; Chen M; Fu X; Zhang Q; Cui Y; Hu X; Zhou W
Med Oncol; 2023 Dec; 41(1):9. PubMed ID: 38063931
[TBL] [Abstract][Full Text] [Related]
16. Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment.
Poojan S; Bae SH; Min JW; Lee EY; Song Y; Kim HY; Sim HW; Kang EK; Kim YH; Lee HO; Hong Y; Park WY; Jang H; Hong KM
Exp Mol Med; 2020 Jul; 52(7):1102-1115. PubMed ID: 32661348
[TBL] [Abstract][Full Text] [Related]
17. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin Resistance: Genetic and Epigenetic Factors Involved.
Lugones Y; Loren P; Salazar LA
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291573
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
